Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis

By Mori Shunsuke   Hirose Jun   Yonemura Kensuke  

Clinical Rheumatology, Vol. 29, Iss. 12, 2010-12 ,pp. : 1357-1366

Springer Publishing Company

Access to resources Recommend Favorite

Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis

By Rodriguez-Rodriguez L   Jover-Jover JA   Fontsere O   Peña-Blanco RC   León L   Fernández-Gutierrez B   Abásolo L  

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 6, 2013-11 ,pp. : 433-436

Informa Healthcare

Access to resources Recommend Favorite

Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up

By Tiippana-Kinnunen T   Paimela L   Kautiainen H   Laasonen L   Leirisalo-Repo M  

Scandinavian Journal of Rheumatology, Vol. 39, Iss. 1, 2010-05 ,pp. : 12-18

Informa Healthcare

Access to resources Recommend Favorite

Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs

By Tan Jing  

Clinical Rheumatology, Vol. 31, Iss. 8, 2012-08 ,pp. : 1169-1175

Springer Publishing Company

Access to resources Recommend Favorite

Recurrent infections in a rheumatoid arthritis patient with a primary immunodeficiency, treated with conventional and biologic disease-modifying anti-rheumatic drugs

By Diamantopoulos Andreas  

Modern Rheumatology, Vol. 22, Iss. 2, 2012-04 ,pp. : 295-297

Springer Publishing Company

Access to resources Recommend Favorite